ArticleJournal of immunology research2020
ILC2 Proliferated by IL-33 Stimulation Alleviates Acute Colitis in Rag1
Article in Journal of immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 23 citations in OpenAlex.
- Pathogenic group 2 innate lymphoid cells as drivers of lung fibrosis in severe asthma.Frontiers in immunology · 2026Review
- ILC plasticity in intestinal immune barrier remodeling: current evidence and therapeutic implications for inflammatory bowel disease.Frontiers in immunology · 2026Review
- Group 2 innate lymphoid cells derived IL-9 reduces macrophage apoptosis and attenuates acute lung injury in sepsis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Immunometabolic programming of macrophages in asthma pathogenesis and therapy.Frontiers in physiology · 2025Review
- Immunological perspectives on atherosclerotic plaque formation and progression.Frontiers in immunology · 2024Review
- Ring1a protects against colitis through regulating mucosal immune system and colonic microbial ecology.Gut microbes · 2023Article
- Innate immune cellular therapeutics in transplantation.Frontiers in transplantation · 2023Article
- Recombinant Expression of Human IL-33 Protein and Its Effect on Skin Wound Healing in Diabetic Mice.Bioengineering (Basel, Switzerland) · 2022Article
- ILCs-Crucial Players in Enteric Infectious Diseases.International journal of molecular sciences · 2022Review
- EnterotoxigenicInfection and immunity · 2022Article
- Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review.International journal of molecular sciences · 2022Review
- Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity.International journal of molecular sciences · 2022Review
- Heterogeneity of ILC2s in the Intestine; Homeostasis and Pathology.Frontiers in immunology · 2022Review
- ILC2s expanded by exogenous IL-33 regulate CD45+CD11b+F4/80high macrophage polarization to alleviate hepatic ischemia-reperfusion injury.Frontiers in immunology · 2022Article
- Cutaneous Wound Healing: A Review about Innate Immune Response and Current Therapeutic Applications.Mediators of inflammation · 2022Review
- Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome.Frontiers in cell and developmental biology · 2022Review
- Type 2 immunity in intestinal homeostasis and inflammatory bowel disease.Biochemical Society transactions · 2021Review
- A crosstalk between type 2 innate lymphoid cells and alternative macrophages in lung development and lung diseases (Review).Molecular medicine reports · 2021Review
- Tissue-Specific Molecular Markers and Heterogeneity in Type 2 Innate Lymphoid Cells.Frontiers in immunology · 2021Review
- IL-33 Drives Expansion of Type 2 Innate Lymphoid Cells and Regulatory T Cells and Protects Mice From Severe, Acute Colitis.Frontiers in immunology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was to identify functions of ILC2, a newly found innate lymphoid cell which mainly locates in mucosa organs like lungs and intestines, in IBD. We injected rIL-33 protein to C57/BL6 mouse to explore how IL-33 induces ILC2 proliferation. The results showed that ILC2 reached a proliferation peak at day 5 and expressed multiple surface markers like CD127, C-kit, CD69, CD44, ST2, CD27, DR3, MHCII, and CD90.2. ILC2 also expressed high quantity of IL-13 and IL-5 and few IL-17A which indicates a potentially immunological function in IBD development. Afterwards, we transferred sort purified ILC2 to Rag1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.